Breast Cancer News

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

An increasing number of oral anticancer drugs have been granted FDA approval and introduced into clinical practice.

SAN ANTONIO — A symptom pattern model predicted risk for immune-related adverse events among women with early-stage, high-risk breast cancer, according to an analysis of the phase 2 I-SPY2 trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Lumpectomy followed by radiation therapy resulted in low rates of local recurrence at 5 years among women with multiple ipsilateral breast cancer, according to phase 2 study results.

SAN ANTONIO — Use of low-dose tamoxifen conferred a sustained reduction in risk for recurrence among women with noninvasive breast cancer, according to updated results from the randomized, phase 3 TAM-01 trial.

The commercial insurance costs for breast reconstruction vary greatly across the United States, with less competitive markets and large, for-profit and nonsafety-net hospitals seeing the highest rates.

Monica M. Bertagnolli, MD, FACS, FASCO, director of the NCI, announced today that she has been diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer.

In this episode of Meeting Mic, we bring you the highlights and insights from the SABCS 2022, as well as Healio’s top headlines from the meeting.

In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more.